1 / 84

PRE TEST

DIPHTHERIA The Past, Present & the Future Dr Cummings Henry Consultant Paediatrician DELSUTH. PRE TEST. Diphtheria has been eradicated The is a resurgence of diphtheria The mainstay of treatment is antibiotics

stacy-armstrong
Télécharger la présentation

PRE TEST

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DIPHTHERIAThe Past, Present & the Future Dr Cummings HenryConsultant PaediatricianDELSUTH

  2. PRE TEST • Diphtheria has been eradicated • The is a resurgence of diphtheria • The mainstay of treatment is antibiotics • Vaccination remain the most effective control measure.

  3. Outline • The Past • The Present • The future

  4. Diphtheria, The Past: • Introduction • Epidemiology • Aetio-pathogenesis • Immunology • Clinical Presentation • Complications • Differentials • Investigations • Treatment • Prognosis • Prevention

  5. Introduction • An ancient disease described by Hippocrates in the 5th century BC • Plagued Europe & the American colonies in the 18th century • Diphtheria is an acute toxic infectious disease • A localized infection of mucous membrane &/or skin • May have systemic complications/manifestations

  6. Epidemiology • Reservoir - Exclusively in humans - Skin infection and skin carriage constitute silent reservoir • Mode of spread * primarily by airborne respiratory droplets * direct contact with; -respiratory secretions of infected individuals -exudates from infected skin lesions

  7. Epidemiology contd. • In the U.S - Pre-vaccination era(1920s) > 115,000 cases and 10,000 deaths reported annually - Recently, < 5 cases are reported annually • In Nigeria - 5,039 cases reported in 1989 - 3,995 cases in 2000 - 2,468 cases in 2001 - 312 cases in 2006 (7.8% of global report)

  8. Epidemiology contd. • Carriers are important in transmission - constitute 3-5% of healthy individuals in endemic region • Estimated mortality rates→5-10% (up to 20% in <5yrs, & > 40yrs)

  9. Epidemiology contd. • Sex No significant difference in the incidence in males & females of similar immunization status • Age - Commoner in 6month-12yrs (esp. in the pre-vaccination era)

  10. Risk factors • Incomplete or absent immunization • Low herd immunity • Travel to endemic areas or regions with current epidemic • Immunocompromised states e.g. HIV/AIDS • Low socio-economic status • Poor health care facilities • Overcrowding

  11. Aetio-pathogenesis • Caused by toxigenic Corynebacterium diphtheriae • Types - Corynebacterium diphtheriae * mitis * intermedius * belfanti * gravis - Corynebacterium ulcerans- causes cutaneous disease

  12. Characteristics • Gram positive • Club-shaped bacillus • Aerobic • Non-motile • Non-encapsulated • About 2-4μm in length • Assume L &/or V configuration to each other • Form a Chinese lettering pattern

  13. Corynebacterium diphtheria

  14. Gram stain Methylene blue stain Corynebacterium diphtheria

  15. Virulence • Depends on the ability to produce the diphtheria toxin-an exotoxin • Toxigenicity depends on the presence of a lysogenic bacteriophage • Non-toxigenic strain can become toxigenic by coming in contact with toxigenic strains

  16. B-phage that carries the tox gene that encodes the diphtheria toxin

  17. The Exotoxin • A 62,000 dalton polypeptide • Composed of 2 joined major segments (A and B)

  18. Actions of the Toxin • Segment B bind receptors on susceptible cells and facilitate entrance of segment A • Segment A mediates toxic actions: - inactivates RNA translocase - inhibits protein synthesis - causing tissue necrosis

  19. Actions of The Toxin contd. • Formation ofpseudomembrane * a dense necrotic coagulum of organism, epithelial cells, fibrin, leucocytes & RBCs * grayish-white or brown in colour

  20. Histological Gross The Pseudomembrane

  21. Other effects of the toxin • Paralysis of palate & hypopharynx • Systemic absorption: - renal tubules necrosis - thrombocytopenia - cardiomyopathy - demyelination of nerves - paralysis of the diaphragm • The toxin is converted to toxoid (for vaccination) when treated with formalin

  22. Immunology • Organisms invasion usually remain localized • The main immune response is to the exotoxin • Immune response is antibody-mediated • The antibody is of the IgG type – Antitoxin • Immunity does not prevent colonization rather it protects against the effects of the toxin

  23. Immunology Contd. • Active antibodies production may be induced by: - active disease - carrier state - vaccination with the toxoid • Passive immunity –transplacentally transferred • Immunity was previously thought to be life long

  24. Assessment of immunity • The Schick test: - Intradermal injection of 0.1ml 1:50 dilution of toxin - positive result: inflammation appearing after 24-36hrs & persisting for ≥ 4days – no antitoxin – no immunity - negative result – has antitoxin - immune

  25. Immunity assessment contd. • Assay of serum level of antitoxin - full protection: ≥0.1IU/mL - basic protection: ≥0.01- <0.1IU/mL - no protection : < 0.01IU/mL N.B: Epidemic outbreak is likely when > 90% of the population has < 0.01IU/mL of antitoxin

  26. Clinical Presentation • Incubation: usually 2-4days with a range of 1-7days • Classified into: - Respiratory Tract Diphtheria - Non-Respiratory Tract disease - Complicated disease

  27. Respiratory tract diphtheria • Nasal Diphtheria - commoner in infants - little or no constitutional symptoms - serosanguineous nasal discharge - epistaxis

  28. Nasal Diphtheria contd. • - purulent foul smelling discharge - shallow ulcers +/- pseudomembrane - unilateral or bilateral - may persist for several weeks - major source of transmission

  29. Tonsilo-Pharyngeal • Most common (90% of cases) • Malaise • Fever – mild to moderate • Sore throat – drooling, odynophagia +/- dysphagia • Bull-neck appearance • Pseudomembrane of variable extent

  30. Bull-Neck appearance

  31. Pseudomenbrane

  32. Laryngeal Diphtheria • Usually an extension of pharyngeal disease • Hoarseness of voice • Cough • Inspiratory stridor

  33. Laryngeal Diphtheria contd. • Suprasternal, substernal & subcostal recessions • Symptoms & signs of sudden airway obstruction • Sudden death • May require intubation/tracheotomy

  34. Tracheo-bronchial diphtheria • Usually an extension from pharynx & larynx • Diphtheria pneumonia – hemorrhagic • Bronchiolar pseudomembrane • Airway obstruction/sudden death

  35. Diphtheria Pneumonia

  36. Non-Respiratory disease

  37. Cutaneous diphtheria

  38. Cutaneous diphtheria • superficial, non-healing ulcers • well defined margins • pseudomembrane on floor of ulcer • erythema & tenderness of surrounding skin • important in transmission in the community

  39. Cutaneous diphtheria contd. • Predisposing factors: - pre-existing dermatoses - laceration - burns - bites - impetigo

  40. Other non-respiratory disease • Ear- otitis externa • Eye – purulent and ulcerative conjunctivitis • Genital tract – purulent and ulcerative vulvo-vaginitis • Rarely septicaemia

  41. Complications • Toxic Cardiomyopathy - commonly myocarditis, rarely endocarditis - usually occurs at the end of 2nd wk of illness - tachycardia out of proportion to fever - arrhythmias - symptoms & signs of CCF - occurs in 10-25% of patients - accounts for 50-60% of deaths

  42. Toxic Cardiomyopathy contd. • ECG findings: - prolonged PR interval - ST segment elevation - 1st, 2nd, or 3rd degree heart block • Echocardiogram: - dilated cardiomyopathy - hypertrophic cardiomyopathy - vegetations

  43. Toxic Neuropathy • Usually occurs at 3-4wks • Affects mainly motor functions • Paralysis of soft palate &pharyngeal wall - nasal voice - difficulty in swallowing (esp. fluids)

  44. Toxic Neuropathy contd. • Occulomotor N. & cillary paralysis - strabismus &/or blurred vision • Peripheral neuritis – diminished DTR & paralysis - occasionally glove & stockings neuropathy ( like GBS) • Paralysis of the diaphragm

  45. Airway obstruction • Commoner in laryngeal disease • May be sudden • Usually due to dislodgement of Pseudomembrane • May require intubation/tracheotomy & mechanical ventilation

  46. Differentials • Tonsillo-Pharyngitis • Viral Croup • Epiglottitis • Peritonsilar abscess • Angioedema • Myocarditis (other causes) • Peripheral neuropathy 2o GBS

  47. Laboratory Studies • Methylene blue &/or gram staining • Culture using tellurite-Loeffler media • Toxigenicity test: - Elek test - PCR

  48. Laboratory studies contd. • FBC – moderate leucocytosis • Urinalysis – transient proteinuria • Serum assay of antibodies – immunity • Serum assay of troponin 1 – myocarditis

  49. Radiological studies • Echocardiogram & ECG findings • Neck soft tissue X-ray – prevertebral soft tissue swelling:

More Related